Your browser doesn't support javascript.
Acute and Postacute COVID-19 Outcomes Among Immunologically Naive Adults During Delta vs Omicron Waves.
Doll, Margaret K; Waghmare, Alpana; Heit, Antje; Levenson Shakoor, Brianna; Kimball, Louise E; Ozbek, Nina; Blazevic, Rachel L; Mose, Larry; Boonyaratanakornkit, Jim; Stevens-Ayers, Terry L; Cornell, Kevin; Sheppard, Benjamin D; Hampson, Emma; Sharmin, Faria; Goodwin, Benjamin; Dan, Jennifer M; Archie, Tom; O'Connor, Terry; Heckerman, David; Schmitz, Frank; Boeckh, Michael; Crotty, Shane.
  • Doll MK; Department of Population Health Sciences, Albany College of Pharmacy & Health Sciences, Albany, New York.
  • Waghmare A; Division of Infectious Diseases, Department of Pediatrics, University of Washington, Seattle.
  • Heit A; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington.
  • Levenson Shakoor B; Amazon, Seattle, Washington.
  • Kimball LE; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California.
  • Ozbek N; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington.
  • Blazevic RL; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington.
  • Mose L; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington.
  • Boonyaratanakornkit J; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington.
  • Stevens-Ayers TL; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington.
  • Cornell K; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington.
  • Sheppard BD; St Luke's Medical Center, Ketchum, Idaho.
  • Hampson E; St Luke's Medical Center, Ketchum, Idaho.
  • Sharmin F; St Luke's Medical Center, Ketchum, Idaho.
  • Goodwin B; Department of Population Health Sciences, Albany College of Pharmacy & Health Sciences, Albany, New York.
  • Dan JM; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California.
  • Archie T; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California.
  • O'Connor T; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla.
  • Heckerman D; St Luke's Medical Center, Ketchum, Idaho.
  • Schmitz F; St Luke's Medical Center, Ketchum, Idaho.
  • Boeckh M; Department of Emergency Medicine, University of Washington, Seattle.
  • Crotty S; Amazon, Seattle, Washington.
JAMA Netw Open ; 6(2): e231181, 2023 02 01.
Article in English | MEDLINE | ID: covidwho-2257409
ABSTRACT
Importance The US arrival of the Omicron variant led to a rapid increase in SARS-CoV-2 infections. While numerous studies report characteristics of Omicron infections among vaccinated individuals or persons with previous infection, comprehensive data describing infections among adults who are immunologically naive are lacking.

Objectives:

To examine COVID-19 acute and postacute clinical outcomes among a well-characterized cohort of unvaccinated and previously uninfected adults who contracted SARS-CoV-2 during the Omicron (BA.1/BA.2) surge, and to compare outcomes with infections that occurred during the Delta wave. Design, Setting, and

Participants:

This prospective multisite cohort study included community-dwelling adults undergoing high-resolution symptom and virologic monitoring in 8 US states between June 2021 and September 2022. Unvaccinated adults aged 30 to less than 65 years without an immunological history of SARS-CoV-2 who were at high risk of infection were recruited. Participants were followed for up to 48 weeks, submitting regular COVID-19 symptom surveys and nasal swabs for SARS-CoV-2 polymerase chain reaction (PCR) testing. Data were analyzed from May to October 2022. Exposures Omicron (BA.1/BA.2 lineages) vs Delta SARS-CoV-2 infection, defined as a positive PCR test result that occurred during a period when the variant represented at least 50% of circulating SARS-CoV-2 variants in the participant's geographic region. Main Outcomes and Measure(s) The main outcomes examined were the prevalence and severity of acute (≤28 days after onset) and postacute (≥5 weeks after onset) symptoms.

Results:

Among 274 participants who were immunologically naive (mean [SD] age, 49 [9.7] years; 186 [68%] female; 19 [7%] Hispanic participants; 242 [88%] White participants), 166 (61%) contracted SARS-CoV-2. Of these, 137 infections (83%) occurred during the Omicron-predominant period and 29 infections (17%) occurred during the Delta-predominant period. Asymptomatic infections occurred among 7% (95% CI, 3%-12%) of Omicron-wave infections and 0% (95% CI, 0%-12%) of Delta-wave infections. Health care use among individuals with Omicron-wave infections was 79% (95% CI, 43%-92%) lower relative to individuals with Delta-wave infections (P = .001). Compared with individuals infected during the Delta wave, individuals infected during the Omicron wave also experienced a 56% (95% CI, 26%-74%, P = .004) relative reduction in the risk of postacute symptoms and a 79% (95% CI, 54%-91%, P < .001) relative reduction in the rate of postacute symptoms. Conclusions and Relevance These findings suggest that among adults who were previously immunologically naive, few Omicron-wave (BA.1/BA.2) and Delta-wave infections were asymptomatic. Compared with individuals with Delta-wave infections, individuals with Omicron-wave infections were less likely to seek health care and experience postacute symptoms.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Topics: Long Covid / Vaccines / Variants Limits: Adult / Female / Humans / Male / Middle aged Language: English Journal: JAMA Netw Open Year: 2023 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Topics: Long Covid / Vaccines / Variants Limits: Adult / Female / Humans / Male / Middle aged Language: English Journal: JAMA Netw Open Year: 2023 Document Type: Article